Cargando…

Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib

Detalles Bibliográficos
Autores principales:	Bardy-Bouxin, Nathalie, Matczak, Ewa, Devgan, Geeta, Woloj, Mabel, Shapiro, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340369/ https://www.ncbi.nlm.nih.gov/pubmed/25733805 http://dx.doi.org/10.2147/BTT.S79507

Ejemplares similares

Resistant mutations in CML and Ph(+)ALL – role of ponatinib
por: Miller, Geoffrey D, et al.
Publicado: (2014)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Nicotinamide–Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds
por: Larocque, Elizabeth, et al.
Publicado: (2020)

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
por: Čuřík, Nikola, et al.
Publicado: (2023)

Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study
por: Hofman, Susan, et al.
Publicado: (2023)

Reply by McCormack et al. to Townsend and Cowl, and to Miller et al.
por: McCormack, Meredith, et al.
Publicado: (2022)

Reply by Elmaleh-Sachs et al. to Townsend and Cowl, and to Miller et al.
por: Elmaleh-Sachs, Arielle, et al.
Publicado: (2022)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
por: Noetzli, Jasmine, et al.
Publicado: (2017)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment
por: Hayashi, Kunio, et al.
Publicado: (2021)

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
por: Jabbour, Elias, et al.
Publicado: (2023)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2015)

Reply to Miller et al.: Airway Disease Presenting as Restrictive Impairment
por: Eddy, Rachel L.
Publicado: (2020)

Do GRE scores help predict getting a physics Ph.D.? A comment on a paper by Miller et al.
por: Weissman, M. B.
Publicado: (2020)

CML Developing Three Years after Therapy Completion in a Child with Ph(−) Pre-B-ALL
por: Hosseini, S., et al.
Publicado: (2011)

P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL
por: Breccia, Massimo, et al.
Publicado: (2023)

Cytogenetic alterations in CML: not all created equal
por: Gong, Zimu, et al.
Publicado: (2018)

Ponatinib‐induced ichthyosiform eruption
por: Kluger, Nicolas, et al.
Publicado: (2021)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

Eruptive melanocytic nevi associated with ponatinib
por: Devred, Inès, et al.
Publicado: (2018)

Ponatinib-Induced Cerebrovascular Accident (CVA)
por: Azad, Farhan, et al.
Publicado: (2022)

Reengineering Ponatinib to Minimize Cardiovascular Toxicity
por: Hnatiuk, Anna P., et al.
Publicado: (2022)

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): An Update
por: Zhang, Heyang, et al.
Publicado: (2021)

P371: PONATINIB AS A PROPHYLACTIC OR PRE-EMPTIVE STRATEGY TO PREVENT CYTOLOGICAL RELAPSE AFTER ALLO-SCT IN PATIENTS WITH PH POS ALL TRANSPLANTED IN COMPLETE CYTOLOGICAL REMISSION
por: Candoni, Anna, et al.
Publicado: (2023)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

Correction: Miller et al. Behavioral Diversity as a Potential Indicator of Positive Animal Welfare. Animals 2020, 10, 1211
por: Miller, Lance J., et al.
Publicado: (2023)

Henry Miller
por: Widmer, Kingsley, 1925-
Publicado: (1975)

Arthur Miller
por: Hayman, Ronald, 1932-
Publicado: (1970)

Miller, Anestesia
Publicado: (2016)

Luisa Miller
por: Verdi, Giuseppe, 1813-1901
Publicado: (1988)

Luisa Miller
por: Verdi, Giuseppe, 1813-1901
Publicado: (1988)

Henry Miller
por: Widmer, Kingsley, 1925-
Publicado: (1974)

Miller, Anestesia
Publicado: (2010)

Miller anestesia /
Publicado: (2005)

The Miller Hospital
Publicado: (1902)

Cannot write session to /tmp/vufind_sessions/sess_ig9cm48fv45cn8o649cokvkv0m